MedTrace Logo

Clinical Trial Comparing Gemcitabine and Vandetanib Therapy With Gemcitabine Alone in Pancreatic Carcinoma

NCT01601808 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 142

Last updated 2025-03-13

No results posted yet for this study

Summary

ViP is a double blinded clinical trial which will compare gemcitabine and vandetanib chemotherapy with gemcitabine alone in patients with locally advanced or metastatic pancreatic carcinoma.

Conditions

Interventions

DRUG

Placebo

Orally once a day, continuously throughout the study

DRUG

Caprelsa (vandetanib)

Orally once a daily, continuously throughout the study.

Sponsors & Collaborators

  • AstraZeneca

    collaborator INDUSTRY

  • University of Liverpool

    lead OTHER

Principal Investigators

  • Dr Gary Middleton · Royal Surrey County Hospital NHS Foundation Trust

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-10-10
Primary Completion
2018-09-05
Completion
2018-09-05

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01601808 on ClinicalTrials.gov